Description

Buy Erdafitinib at China Peptide

Buy Erdafitinib a fibroblast growth factor receptor tyrosine kinase inhibitor used to treat locally advanced or metastatic urothelial carcinoma. In early April 2019, the US Food and Drug Administration (FDA) approved Janssen Pharmaceutical Company’s Balversa (erdafitinib) brand as the world’s first fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma with responsive FGFR3 or FGFR2 genetic alterations that have progressed during or after platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

 

The innovation of erdafitinib is that it is the first personalized treatment targeting sensitive FGFR genetic alterations for patients with metastatic bladder cancer, demonstrating the design of erdafitinib in the development of more personalized and precise drugs that can target cancer treatment to a patient’s specific genetic mutation. Given that urothelial cancer is statistically the fourth most common cancer worldwide, the arrival of erdafitinib offers a welcome new option in the ever-expanding therapeutic toolbox for the treatment of such common diseases.

 

Erdafitinib was given Breakthrough Therapy Designation and Accelerated Approval by the FDA to allow the agency to focus on and expedite the approval process for a drug indicated to treat a serious condition that addresses an unmet medical need using clinical trial data that is believed to predict real clinical benefit for patients with the condition. Such designations mean that further ongoing clinical trials are needed to confirm the clinical benefit of erdafitinib in the future.